Insulin resistance as risk factor for the development of type 2 diabetes mellitus: a systematic approach

1. Cefalu WT. Insulin resistance: Cellular and clinical concepts. Exp Biol Med. 2001;226(1):13–26.10.1177/15353702012260010311368233Search in Google Scholar

2. Zapata-Bustos R, Finlayson J, Langlais PR, Coletta DK, Luo M, Grandjean D, et al. Altered transcription factor expression responses to exercise in insulin resistance. Front Physiol. 2021;12:649461.10.3389/fphys.2021.649461805836833897458Search in Google Scholar

3. Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev. 2019;40(6):1447-67.10.1210/er.2018-00141744541931050706Search in Google Scholar

4. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1(4):312-28.10.1016/j.jhepr.2019.07.002700155732039382Search in Google Scholar

5. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34.10.1016/j.pcd.2021.04.004803125933849817Search in Google Scholar

6. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1-58.10.1002/cphy.c110062412966123720280Search in Google Scholar

7. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(2):S112-9.10.2337/dc07-s20217596458Search in Google Scholar

8. Kelsey MM, Zeitler PS. Insulin Resistance of Puberty. Curr Diab Rep. 2016;16(7):64.10.1007/s11892-016-0751-527179965Search in Google Scholar

9. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: A review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708.10.1016/j.biopha.2020.11070832927252Search in Google Scholar

10. Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2011;73(04):460-6.10.4088/JCP.10m0682222225552Search in Google Scholar

11. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol. 2018;175:177-89.10.1016/j.jsbmb.2016.09.01727662816Search in Google Scholar

12. Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity - correlation with gold standard is not enough. BMC Med Res Methodol. 2018;18(1):64.10.1186/s12874-018-0521-y601983129940866Search in Google Scholar

13. Lee CH, Shih AZ, Woo YC, et al. Optimal Cut-Offs of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to Identify Dysglycemia and Type 2 Diabetes Mellitus: A 15-Year Prospective Study in Chinese. PLoS One. 2016;11(9):e0163424.10.1371/journal.pone.0163424503357027658115Search in Google Scholar

14. Singh Y, Garg MK, Tandon N, Marwaha RK. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5(4):245-51.10.4274/Jcrpe.1127389022424379034Search in Google Scholar

15. Alebić MŠ, Bulum T, Stojanović N, Duvnjak L. Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine. 2014;47(2):625-30.10.1007/s12020-014-0182-524522614Search in Google Scholar

16. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010;1(2):36-47.10.4239/wjd.v1.i2.36308388421537426Search in Google Scholar

17. Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 2020;472(9):1273-98.10.1007/s00424-020-02417-x746292432591906Search in Google Scholar

18. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(2):S157-S163.10.2337/dc09-S302281143619875544Search in Google Scholar

19. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315.10.1016/j.biopha.2021.11131533561645Search in Google Scholar

20. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33(2):431-53.10.1016/j.ecl.2004.03.00815158528Search in Google Scholar

21. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121.10.1186/s12944-015-0123-1Search in Google Scholar

22. Bazotte RB, Silva LG, Schiavon FP. Insulin resistance in the liver: deficiency or excess of insulin?. Cell Cycle. 2014;13(16):2494-500.10.4161/15384101.2014.947750Search in Google Scholar

23. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283-303.10.1016/j.ecl.2004.03.002Search in Google Scholar

24. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci. World J. 2015;2015:479354.Search in Google Scholar

25. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J CardioMetab Syndr. 2009;4(2):113–9.10.1111/j.1559-4572.2008.00044.xSearch in Google Scholar

26. Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813–20.10.2337/dc16-2736Search in Google Scholar

27. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(6a):9S–14S.10.1016/S0002-9343(00)00337-5Search in Google Scholar

28. Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. J Endocr Soc. 2019;3(9):1727-47.10.1210/js.2019-00065673575931528832Search in Google Scholar

29. Jung SH, Jung CH, Reaven GM, Kim SH. Adapting to insulin resistance in obesity: role of insulin secretion and clearance. Diabetologia. 2018;61(3):681-7.10.1007/s00125-017-4511-0609513729196782Search in Google Scholar

30. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91.10.1210/jc.2005-033116076947Search in Google Scholar

31. Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V et al. Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest. 2002;25(6):532–8.10.1007/BF0334549612109625Search in Google Scholar

32. Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab. 2015;100(8):2946-55.10.1210/jc.2015-1917452499426037515Search in Google Scholar

33. Winhofer Y, Wolf P, Krššák M, Wolfsberger S, Tura A, Pacini G et al. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2014;99(11):4299-306.10.1210/jc.2014-224225148232Search in Google Scholar

34. Vila G, Jørgensen JOL, Luger A, Stalla GK. Insulin Resistance in Patients With Acromegaly. Front Endocrinol (Lausanne). 2019;10:509.10.3389/fendo.2019.00509668366231417493Search in Google Scholar

35. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.10.2337/db09-9028266158219336687Search in Google Scholar

36. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52(5):549-55.10.1046/j.1365-2265.2000.00986.x10792333Search in Google Scholar

37. Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders - treatment options. Endokrynol Pol. 2017;68(3):334-51.10.5603/EP.2017.002628660991Search in Google Scholar

38. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702–11.10.1210/jc.2011-3123333989022419708Search in Google Scholar

39. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2002;290(3):1084-9.10.1006/bbrc.2001.630711798186Search in Google Scholar

40. Gierach M, Gierach J, Junik R. Insulin resistance and thyroid disorders. Endokrynol Pol. 2014;65:70-6.10.5603/EP.2014.001024549605Search in Google Scholar

41. B UU, Mn S, Km S, Prashant A, Doddamani P, Sv S. Effect of insulin resistance in assessing the clinical outcome of clinical and subclinical hypothyroid patients. J Clin Diagn Res. 2015;9(2):OC01-OC4.10.7860/JCDR/2015/9754.5513437875925859477Search in Google Scholar

42. Vyakaranam S, Vanaparthy S, Nori S, Palarapu S, Bhongir AV. Study of Insulin Resistance in Subclinical Hypothyroidism. Int J Health Sci Res. 2014;4(9):147-53.Search in Google Scholar

43. Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf). 2008;69(6):963–9.10.1111/j.1365-2265.2008.03280.x18429948Search in Google Scholar

44. Harikrishna A, Ishak A, Ellinides A, Saad R, Christodoulou H, Spartalis E, et al. The impact of obesity and insulin resistance on thyroid cancer: A systematic review. Maturitas. 2019;125:45-9.10.1016/j.maturitas.2019.03.02231133216Search in Google Scholar

45. Balkan F, Onal ED, Usluogullari A, Tuzun D, Ozdemir D, Inancli SS, et al. „Is there any association between insulin resistance and thyroid cancer? : A case control study”. Endocrine. 2014;45(1):55–60.10.1007/s12020-013-9942-x23564559Search in Google Scholar

46. Heidari Z, Abdani M, Mansournia MA. Insulin Resistance Associated With Differentiated Thyroid Carcinoma: Penalized Conditional Logistic Regression Analysis of a Matched Case-Control Study Data. Int J Endocrinol Metab. 2017;16(1):e14545.10.5812/ijem.14545590338229696038Search in Google Scholar

47. Klubo-Gwiezdzinska J, Costello J, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):3269–79.10.1210/jc.2012-379923709654Search in Google Scholar

48. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. Int J Adolesc Med Health. 2021 Jul 22 [published online ahead of print]. DOI: 10.1515/ijamh-2021-0073.10.1515/ijamh-2021-007334293835Search in Google Scholar

49. Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2:56.Search in Google Scholar

50. Moghetti P. Insulin Resistance and Polycystic Ovary Syndrome. Curr Pharm Des. 2016;22(36):5526-34.10.2174/138161282266616072015585527510482Search in Google Scholar

51. Li H, Chen Y, Yan LY, Qiao J. Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS. Endocrine. 2013;43(1):184-90.10.1007/s12020-012-9739-322798247Search in Google Scholar

52. Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016;16(1):53-60.10.1016/j.repbio.2015.12.00626952754Search in Google Scholar

53. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21.10.1016/j.cca.2019.11.00331733195Search in Google Scholar

54. Al-Sulaiti H, Diboun I, Agha MV, Mohamed FF, Atkin S, Dömling AS, et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J Transl Med. 2019;17(1):348.10.1186/s12967-019-2096-8Search in Google Scholar

55. Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne). 2019;10:703.10.3389/fendo.2019.00703Search in Google Scholar

56. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30(5):1200-5.10.2337/dc06-2416Search in Google Scholar

57. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226-8.10.1016/S0140-6736(03)12255-6Search in Google Scholar

58. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359(9300):46-7.10.1016/S0140-6736(02)07281-1Search in Google Scholar

59. Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21(3):403-16.10.1016/j.cmet.2015.02.006Search in Google Scholar

60. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11(6):212-7.10.1016/S1043-2760(00)00272-1Search in Google Scholar

61. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020;10:1607.10.3389/fphys.2019.01607700065732063863Search in Google Scholar

62. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146-E150.10.1210/jc.2010-1170303848121047923Search in Google Scholar

63. Chen CC, Kuo CH, Leu YL, Wang SH. Corylin reduces obesity and insulin resistance and promotes adipose tissue browning through SIRT-1 and β3-AR activation. Pharmacol Res. 2021;164:105291.10.1016/j.phrs.2020.10529133253817Search in Google Scholar

64. Kobyliak, N., Falalyeyeva, T., Mykhalchyshyn, Molochek N, Savchuk O, Kyriienko D, et al. Probiotic and omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance, improves glycemia and obesity parameters in individuals with type 2 diabetes: A randomised controlled trial. Obesity Medicine. 2020;19:100248.10.1016/j.obmed.2020.100248Search in Google Scholar

65. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.10.1186/1758-5996-5-6360788923415113Search in Google Scholar

66. Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019;19(12):151.10.1007/s11892-019-1270-y688142931776781Search in Google Scholar

67. Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13(1):23.10.1186/s13098-021-00639-2791999933648564Search in Google Scholar

68. Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte. 2018;7(2):121-28.Search in Google Scholar

69. Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci. 2020;240:117090.10.1016/j.lfs.2019.11709031765648Search in Google Scholar

70. Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299-308.10.1111/1471-0528.1475428544572Search in Google Scholar